Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management (Companion Faculty Lecture)
Research To Practice | Oncology Videos · Dr. Neil Love
July 28, 202539m 1s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics:
- Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00)
- Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49)
- Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44)
- Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29)
- Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19)